BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 19837760)

  • 21. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
    du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of animal handling on the results of 18F-FDG PET studies in mice.
    Fueger BJ; Czernin J; Hildebrandt I; Tran C; Halpern BS; Stout D; Phelps ME; Weber WA
    J Nucl Med; 2006 Jun; 47(6):999-1006. PubMed ID: 16741310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
    Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
    Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
    Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
    Cornelissen B; Kersemans V; McLarty K; Tran L; Vallis KA; Reilly RM
    Nucl Med Biol; 2009 Oct; 36(7):811-9. PubMed ID: 19720293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN; Andriu A; Smith TA
    Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
    Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
    Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
    Rybczynska AA; de Bruyn M; Ramakrishnan NK; de Jong JR; Elsinga PH; Helfrich W; Dierckx RA; van Waarde A
    J Nucl Med; 2013 Sep; 54(9):1613-20. PubMed ID: 23940303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
    Cheyne RW; Trembleau L; McLaughlin A; Smith TA
    Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper.
    Jensen MM; Jørgensen JT; Binderup T; Kjaer A
    BMC Med Imaging; 2008 Oct; 8():16. PubMed ID: 18925932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.